Cooper University Health Care First in the Region to Implant Next-Generation WATCHMAN FLX(TM) Device
Cooper is one of approximately 40 sites in the United States and the only hospital in the Philadelphia region participating in a clinical trial for Boston Scientific’s WATCHMAN FLX™ device. The WATCHMAN FLX™ is the next generation of a potentially life-changing catheter-based (or non-surgically delivered) device designed to close the left atrial appendage in order to reduce the risk of stroke in certain patients with atrial fibrillation (AFib). Read more.

Cooper University Health Care was recognized as a top performing hospital for treating congestive heart failure in U.S. News & World Report’s 2018-2019 Best Hospitals survey.